On Monday, Revvity Inc (NYSE:RVTY) stock maintained its positive outlook from Evercore ISI with an Outperform rating and a steady price target of $126.00. The company reported total revenues of $692 million, slightly surpassing short-term expectations, with a -1% organic decline matching the high end of its guidance range.
This performance was attributed to stronger-than-expected diagnostics (Dx) growth, particularly in the ImmunoDx sector, which experienced high single-digit growth against mid single-digit expectations.
The company's diagnostics beat was driven by global ImmunoDx growth, with stable figures in China and low single-digit growth in Reproductive Health, outperforming expectations of slight declines. Despite Applied Genomics seeing low double-digit declines, the results were generally in line with projections.
Life Sciences saw a mid single-digit decline in Pharma/Biotech, contributing to a high single-digit fall in soft reagents, while core reagents outside of licensing also saw a low single-digit decline.
Revvity's gross margins fell slightly below short-term expectations, but effective operating expense management resulted in an operating margin beat, 130 basis points above the short-term forecast.
Higher net interest and other expenses were a 5-cent headwind to earnings per share (EPS), which would have been higher if excluded. The company also reported a strong free cash flow of $160 million, maintaining a 107% conversion rate consistent with first-quarter trends.
Looking forward, Revvity has adjusted its revenue guidance to $2.77 - $2.79 billion, slightly narrowing from the previous $2.76 - $2.82 billion range due to increased foreign exchange headwinds.
The EPS forecast has been raised to $4.70 - $4.80, up from the prior $4.55 - $4.75 estimate, after a 10-cent beat in the second quarter and an approximately 25 basis point operating margin guidance increase at the midpoint.
The company has removed the high end of its organic growth guidance, likely due to more challenging biopharma markets, but maintained its midpoint at 2%. Revvity's consistent results and solid operational execution were highlighted, with further details anticipated following the company's conference call.
In other recent news, Revvity Inc reported its second quarter 2024 revenue at $692 million, aligning with both the company's guidance and the consensus estimate of $690 million.
The company's adjusted earnings per share (EPS) of $1.22 exceeded the consensus forecast of $1.12. By segment, Revvity's Life Sciences division experienced a 6% year-over-year organic decline, while the Diagnostics segment enjoyed a 3% organic growth.
The company has updated its full-year 2024 guidance, projecting revenues to be between $2.77 billion and $2.79 billion, marking an increase of $0.10 from previous estimates.
Citi has maintained a Buy rating and a price target of $135.00 on Revvity, highlighting the company's positive margin performance.
TD Cowen has increased its price target on Revvity to $130.00, while maintaining a Buy rating.
Baird has also updated its financial outlook on Revvity, increasing the price target to $127 from the previous $126 while reaffirming an Outperform rating. These are among the recent developments for Revvity Inc.
InvestingPro Insights
Revvity Inc's (NYSE:RVTY) recent performance and outlook, as reported by Evercore ISI, is complemented by some notable financial metrics and management actions. With a market capitalization of $14.21 billion, the company trades at a forward P/E ratio of 39.35, which may appear elevated, reflecting investor confidence in future earnings. This is further supported by management's aggressive share buyback strategy, as noted in one of the InvestingPro Tips, which can be indicative of leadership's belief in the company's undervaluation. Additionally, Revvity's commitment to shareholder returns is evident through its track record of maintaining dividend payments for 54 consecutive years, a testament to its financial stability and a potential draw for income-focused investors.
While the company's revenue has seen a decline of 9.85% over the last twelve months as of Q1 2024, its high shareholder yield and expected net income growth for the year are positive indicators for future performance. Investors seeking further insights into Revvity's financial health and stock potential can find additional InvestingPro Tips by visiting https://www.investing.com/pro/RVTY. For those interested in a deeper analysis, use the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription, where 11 more tips await to guide your investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.